Drug Profile
Research programme: therapeutic antibodies and peptides - Dyax/Merck
Alternative Names: Therapeutic antibodies and peptides research programme - Dyax/MerckLatest Information Update: 19 Mar 2010
Price :
$50
*
At a glance
- Originator Dyax; Merck & Co
- Developer Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Aug 2005 Preclinical trials in Undefined in USA (unspecified route)